What Is a REMS Program
What is a REMS program?
A REMS (Risk Evaluation and Mitigation Strategy) is a drug safety program that the U.S. FDA can require for certain medicines with serious safety concerns, to help make sure the medicine's benefits outweigh its risks (FDA, REMS overview). Each REMS targets one specific serious risk. It aims to prevent, monitor or manage that risk by "informing, educating and/or reinforcing actions to reduce the frequency and/or severity of the event."
Approach: I used FDA's own REMS pages, the overview and "What's in a REMS?". I didn't search the medicines registries for this definitional question.
Key points
- Only a few drugs need one. All medicines carry labeling that explains their risks. FDA says "only a few medications require a REMS," for cases where labeling alone isn't enough.
- The manufacturer builds it. FDA requires the manufacturer to develop the REMS, and FDA approves it (overview).
- Structure. Each REMS has a risk mitigation goal, communication elements, and required activities for prescribers, pharmacists and patients (What's in a REMS?).
Typical components (What's in a REMS?)
- Medication Guide: usually given to the patient when the medicine is dispensed or administered.
- Communications to healthcare providers: the manufacturer tells prescribers and pharmacists about the risk and the "steps to take to reduce the risk."
- Elements to Assure Safe Use (ETASU): the strictest tools, used for higher-risk products. They include:
- prescriber certification or training
- certification of pharmacies or care settings
- restricted distribution to specific settings
- safe-use conditions, such as documented lab results before dispensing
- patient monitoring during treatment
- enrolment in a patient registry
Example: Zyprexa Relprevv (long-acting injectable olanzapine for schizophrenia) can cause post-injection delirium sedation syndrome. Its REMS requires that it be given only in certified healthcare facilities that can observe patients for at least three hours and treat an adverse event if one occurs (overview).
FDA lists the currently approved programs, with each one's participant requirements and materials, on the REMS@FDA site.
The FDA pages I opened don't give the legal basis for REMS or the schedule for the manufacturer's REMS assessments. I can pull the statute and FDA's REMS assessment guidance next if you need them.
How does the FDA decide a drug needs one?
The FDA requires a REMS when it decides one is "necessary to ensure that the benefits of the drug outweigh the risks of the drug." The law (FD&C Act section 505-1, codified at 21 U.S.C. 355-1) lists six factors the FDA must weigh in making that call [1]. The decision can be made before approval or at any point after it.
Approach: I used the REMS section of the Federal Food, Drug, and Cosmetic Act, in the 2023 U.S. Code edition. FDA's own guidance on how it applies these factors in practice is not in the datasets I can search.
The six factors [1]
- How many people are likely to use the drug.
- How serious the disease or condition being treated is.
- How much benefit the drug is expected to give for that condition.
- How long treatment is expected to last, or actually lasts.
- How serious the known or potential adverse events are, and how often those events already occur in the patients likely to use the drug.
- Whether the drug is a new molecular entity.
Who decides, and when
- Before approval: The FDA makes the decision in consultation with the office that reviews the drug and the office responsible for its safety after approval. It then tells the applicant, who must submit a proposed REMS as part of the application [1].
- After approval: The FDA can require a REMS later if it learns of "new safety information" and decides a REMS is needed. This includes when it acts on a supplement for a new indication. The holder then has 120 days to submit a proposed REMS, unless the FDA sets another reasonable deadline. "New safety information" means data on a serious or unexpected serious risk, or on how well an existing REMS is working. It can come from clinical trials, adverse event reports, post-approval studies, peer-reviewed literature or FDA's postmarket surveillance system [1].
- Seniority: The decision must be made by someone at or above the level allowed to approve a drug, such as a CDER division director [1].
Tighter tests for each added element [1]
Every REMS must at least include a timetable for assessments: at 18 months, at 3 years and in the 7th year. The FDA may drop the assessments after 3 years if it finds the serious risks are adequately managed. Any further element needs its own separate finding:
- Patient package insert: only if it may help mitigate a serious risk. (A Medication Guide can also be required, under 21 CFR part 208.)
- Communication plan to healthcare providers: only if it may support implementation of another part of the REMS.
- Packaging and disposal requirements: only where the drug carries a serious risk of overdose or abuse.
- Elements to Assure Safe Use (ETASU): these have the highest bar. The drug must have been shown to work but be linked to a serious adverse drug experience, and it can be approved only with these elements, or would otherwise be withdrawn. If the drug was first approved without ETASU, the other REMS elements must also not be enough. ETASU must also:
- match the specific serious risk listed in the labeling
- not be unduly burdensome on patient access, especially for seriously ill, rural or underserved patients and those with functional limitations
- fit existing distribution and dispensing systems where practicable
- be posted publicly by the FDA within 30 days, with an explanation of how they reduce the risk
"Serious risk" in all of this means a risk of a serious adverse drug experience. That covers death, an immediate risk of death, hospitalisation or a longer hospital stay, persistent or significant incapacity, a congenital anomaly or birth defect, or an event that may need medical or surgical intervention to prevent one of those outcomes [1].
Generic drugs (ANDAs) are covered by a separate subsection of the same section, which I haven't printed here. I can pull it, or FDA's guidance on how it applies the six factors, next.
Which drugs currently have a REMS?
FDA's REMS@FDA register currently lists 68 approved REMS programs. 56 of them include Elements to Assure Safe Use (ETASU), the strictest tier, and 12 do not. The count is of programs, not individual drugs. Some programs cover a whole group of products under one REMS, such as the Opioid Analgesic REMS [2], the Transmucosal Immediate-Release Fentanyl (TIRF) Products REMS [3], the Buprenorphine Transmucosal Products for Opioid Dependence REMS [4], and the shared-system REMS for alvimopan [5] and tolvaptan for ADPKD [6]. The full list, with approval dates, last-updated dates and the elements each program contains, is in the panel document.
Approach: I took the list from FDA's REMS@FDA register of currently approved programs. The register lists programs by name, so the products and active substances under each shared or class-wide program aren't broken out here.
How the programs break down
- ETASU programs (56): These include the larger restricted-access programs: Isotretinoin iPLEDGE [7], Mifepristone [8], Lenalidomide [9], Sodium Oxybate [10], Spravato [11], Tecvayli and Talvey [12], and Ultomiris and Soliris [13].
- All ETASU programs except the Opioid Analgesic REMS also have an implementation system [2].
- Programs without ETASU (12): All 12 rely on a communication plan. They are:
- Medication Guide as a REMS element (9 programs): the three opioid/buprenorphine class programs above, plus:
Most recent approvals
- Thalidomide REMS, 2 September 2026 [31]
- Zenbexus, 13 August 2026 [32]
- Ponlimsi, 27 March 2026 [24]
- Nexplanon, 16 January 2026 [33]
The oldest program still listed is Zyprexa Relprevv, approved 11 December 2009 [30].
I can pull the full program pages next if you need the specific serious risk, participant requirements or covered products for any of these.